Organization | Azienda USL 4 Prato

Azienda USL 4 Prato Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4

Founded: Prato Italy

Organization Overview

First Clinical Trial

2010

NCT01216020

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Azienda USL 4 Prato - O.C. Misericordia e Dolce | Azienda USL Toscana Centro | Azienda USL Toscana Centro - Prato | Fabrizio Cantini | Hospital of Prato | Hospital of Prato, Italy | Prato Hospital, Italy | USL4 Hospital of Prato, Italy

Active Ingredients

Drugs in Phase 4 Trials (3)

atorvastatin (lipitor) (2 trials)

rosuvastatin (crestor) (1 trial)

tocilizumab (actemra) (1 trial)

Drugs in Phase 3 Trials (1)

baricitinib (olumiant) (2 trials)

Drugs in Phase 2 Trials (13)

anastrozole (arimidex) (2 trials)

cetuximab (erbitux) (1 trial)

cisplatin (platinol) (1 trial)

colchicine (colbenemid) (1 trial)

exemestane (aromasin) (1 trial)

fulvestrant (faslodex) (2 trials)

letrozole (femara) (3 trials)

paclitaxel (taxol) (2 trials)

palbociclib (ibrance) (3 trials)

pertuzumab (perjeta) (1 trial)

ribociclib (kisqali) (1 trial)

trastuzumab (herceptin) (1 trial)

vinorelbine (navelbine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Coronary Syndrome (Phase 4)

Acute Kidney Injury (Phase 4)

Arteritis (Phase 4)

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Giant Cell Arteritis (Phase 4)

Head and Neck Neoplasms (Phase 2)

Laryngeal Neoplasms (Phase 2)

Lung Neoplasms (Phase 2)

Mouth Neoplasms (Phase 2)

Neoplasms (Phase 2)

Pharyngeal Neoplasms (Phase 2)

Pneumonia (Phase 3)

Polymyalgia Rheumatica (Phase 4)

Syndrome (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 12
# of Trial APIs: 17